AQR Capital Management
PRME icon

AQR Capital Management’s Prime Medicine PRME Stock Holding History

AQR Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93M Buy
554,935
+139,114
+33% +$529K ﹤0.01% 2375
2025
Q4 		$1.44M Buy
415,821
+1,610
+0.4% +$7.16K ﹤0.01% 2341
2025
Q3 		$2.29M Sell
414,211
-10,144
-2% -$41.2K ﹤0.01% 1901
2025
Q2 		$1.05M Buy
424,355
+180,560
+74% +$278K ﹤0.01% 2182
2025
Q1 		$485K Buy
243,795
+227,749
+1,419% +$581K ﹤0.01% 2440
2024
Q4 		$46.9K Buy
+16,046
New +$56.3K ﹤0.01% 2811
2024
Q3 		– Sell
-34,268
Closed -$176K – 2857
2024
Q2 		$176K Buy
+34,268
New +$208K ﹤0.01% 2443

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AQR Capital Management's PRME Position: Q1 2026 in Review

AQR Capital Management increased its Prime Medicine (PRME) stake by 33% in Q1 2026, buying an estimated $529K and bringing the position to 554,935 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

AQR Capital Management first reported a position in PRME in Q2 2024 and has held it in 7 quarters since. The position peaked at $2.29M in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • AQR Capital Management held 554,935 shares of Prime Medicine worth $1.93M as of Q1 2026.
  • AQR Capital Management bought 139,114 Prime Medicine shares in Q1 2026, an estimated $529K.
  • Prime Medicine made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2375 holding.
  • AQR Capital Management first reported a position in Prime Medicine in Q2 2024 and has held it in 7 quarters since.
  • AQR Capital Management's Prime Medicine position peaked at $2.29M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.